BioInvent AACR data boost prospects for BI-1808

New translational data for the anti-TNFR2 antibody BI-1808 show dose-dependent biomarker modulation

Lund, Sweden – March 8, 2022 – BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that data regarding the anti-TNFR2 drug candidate BI-1808, currently in clinical development, will be presented at the forthcoming annual meeting of the American Association for Cancer Research in April 2022 (AACR22).

“The exciting translational data that will be presented on BI-1808 clearly show why we are so enthusiastic about our ongoing clinical studies in solid tumors. It is highly encouraging that we see similar biomarker correlations in patient samples as we observe in the preclinical setting” said Martin Welschof, CEO of BioInvent.

BI-1808 is an antibody from BioInvent’s n-CoDeR/F.I.R.S.T™ platform directed against tumor necrosis factor receptor-2 (TNFR2).

The results from the toxicological studies demonstrate a very good tolerability profile, and likewise, there has been no safety concerns in the clinical trial to date. Furthermore, in vivo studies using experimental cancer models showed a clear relationship between dose, receptor occupancy (RO) and efficacy. In both mouse tumor models and in the toxicology studies, soluble TNFR2 was clearly modulated by the treatment and closely correlated with RO. Like in the preclinical studies, correlations between dose, RO and soluble TNFR2 have clearly been observed in patients in the ongoing Phase 1/2a clinical trial.

AACR 2022 will take place on April 8–13, 2022, at the Ernest N. Morial Convention Center – New Orleans, LA, US. The BI-1808 poster is entitled “BI-1808 – a first in class ligand-blocking TNFR2 antibody for cancer immunotherapy” with presentation details as follows:

Session Category: Clinical Research Excluding Trials
Session Title: Vaccines / Immunomodulatory Agents and Interventions
Session Date and Time: Wednesday Apr 13, 2022, 9:00 AM - 12:30 PM CDT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 34
Poster Board Number: 10
Abstract Number: 4156

The abstract can be accessed on the AACR annual meeting website: https://www.aacr.org/meeting/aacr-annual-meeting-2022/.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that
discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer
therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials
for the treatment of hematological cancer and solid tumors, respectively and a fifth program just
initiating clinical development. The Company’s validated, proprietary F.I.R.S.T™ technology
platform simultaneously identifies both targets and the antibodies that bind to them, generating
many promising new drug candidates to fuel the Company’s own clinical development pipeline or
for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with
multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties
in the Company’s fully integrated manufacturing unit. More information is available at www.
bioinvent.com. Follow on Twitter: @BioInvent.

For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com

BioInvent International AB (publ)
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and
forecasts for future scenarios. Predictions for the future only apply as the date they are made and are,
by their very nature, in the same way as research and development work in the biotech segment,
associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly
from the scenarios described in this press release.

Attachments

BioInvent AACR data boost prospects for BI-1808